Outcomes of enteral feeding and other clinical features of the two groups
| Outcomes |
Oral erythromycin group (n=27) |
Placebo group (n=29) |
| Age started on enteral feeding (days) | 6 (4–11) | 8 (5–11) |
| Volume of enteral feeding on enrollment (ml/kg/day) | 43 (17–58) | 51 (39–68) |
| Time after enrollment achieved half enteral feeding (days) | 3.5 (2–7) | 6 (4–11.5)2-150 |
| Time after enrollment achieved three quarters enteral feeding (days) | 8.5 (6–19) | 13 (9–22)2-150 |
| Time after enrollment achieved full enteral feeding (days) | 13.5 (8–22) | 25 (16–33)2-160 |
| Type of milk feeds | ||
| Breast | 5 (19%) | 3 (10%) |
| Formula | 8 (30%) | 8 (28%) |
| Mixed | 14 (51%) | 18 (62%) |
| Exchange tranfusion (n) | 2 (7%) | 2 (7%) |
| Patent ductus arteriosus (n) | 9 (33%) | 13 (45%) |
| Necrotising enterocolitis (n) | 0 (0%) | 0 (0%) |
| Duration of IPPV (days) | 5 (3–11) | 5 (2–15) |
| Duration of mechanical ventilation (days) | 16 (8–30) | 16 (8–36) |
| Duration of O2 dependence (days) | 18 (8–34) | 16 (8–36) |
| Periventricular haemorrhage | ||
| Grade 0–2 | 25 (93%) | 26 (90%) |
| Grade 3–4 | 2 (7%) | 3 (10%) |